Document Detail

Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.
MedLine Citation:
PMID:  15229625     Owner:  NLM     Status:  MEDLINE    
Trials of the efficacy and safety of vardenafil in the treatment of male erectile dysfunction (ED) were meta-analysed. All available databases were searched (January 1, 2001-November 30, 2003). Trials were eligible if they included men with ED, compared vardenafil with placebo, were randomized, were at least of 12 weeks duration, and assessed clinically relevant outcomes. Two reviewers independently evaluated study quality and extracted data in a standardized fashion. Nine trials (6809 men) met the inclusion criteria. In results pooled from seven fixed-dose trials, vardenafil increases the Erectile Function domain of the International Index of Erectile Function questionnaire by 6.18 units (weighted mean difference (WMD)). Vardenafil also increases the percentage of erections firm enough to allow vaginal penetration (WMD: 26) and the percentage of sexual attempts that were successful per participant (WMD: 29.8). The percentage of men agreeing with the statement that 'the treatment they have been taking over the past 4 weeks improved their erections', is also in favour of vardenafil (relative risk (RR): 3). These efficacy variables appeared greater at higher doses, although there are no significant differences between 10 and 20 mg dose. The same results were extracted for the two flexible 'as needed' dosing trials. Discontinuations are greater at the vardenafil groups compared to placebo (RR: 2.25). Specific adverse events with vardenafil included flushing, dyspepsia, headache, and rhinitis. Vardenafil was not significantly associated with serious cardiovascular events or death. Vardenafil, in all treatment regimens, shows to possess superior efficacy to placebo in the treatment of patients with erectile dysfunction. More data is needed on patients' subgroups.
S Markou; P Perimenis; K Gyftopoulos; A Athanasopoulos; G Barbalias
Related Documents :
14671665 - Treatment satisfaction in patients with erectile dysfunction switching from prostagland...
22757655 - Early pain reduction can predict treatment response: results of integrated efficacy ana...
18772695 - Low bone mineral density in spinal muscular atrophy.
12657355 - Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodie...
25170575 - Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
4037555 - Weekly pulse methotrexate in rheumatoid arthritis. clinical and immunologic effects in ...
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  International journal of impotence research     Volume:  16     ISSN:  0955-9930     ISO Abbreviation:  Int. J. Impot. Res.     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-11-23     Completed Date:  2004-12-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007383     Medline TA:  Int J Impot Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  470-8     Citation Subset:  IM    
Akrata Medical Center, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3',5'-Cyclic-GMP Phosphodiesterases
Cyclic Nucleotide Phosphodiesterases, Type 5
Erectile Dysfunction / drug therapy*
Imidazoles / adverse effects,  therapeutic use*
Penile Erection
Phosphodiesterase Inhibitors / therapeutic use*
Phosphoric Diester Hydrolases
Piperazines / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Treatment Outcome
Reg. No./Substance:
0/Imidazoles; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Placebos; 0/Sulfones; 0/Triazines; 224785-90-4/vardenafil; EC 3.1.4.-/Phosphoric Diester Hydrolases; EC',5'-Cyclic-GMP Phosphodiesterases; EC Nucleotide Phosphodiesterases, Type 5; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Changing diagnostic and therapeutic concepts in high-flow priapism.
Next Document:  Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study...